NCT04793685View on ClinicalTrials.gov

Prazosin for Alcohol Use Disorder With Withdrawal Symptoms

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Alcohol Withdrawal
Interventions
DRUG

Prazosin

Prazosin (16mg/day) versus Placebo comparator, with a 2 week titration period, 9 weeks at full dose and a 5-day taper in week 12.

BEHAVIORAL

12-Step Facilitation with Relapse Prevention and Contingency Management

12-Step Facilitation and relapse prevention weekly support and Contingency Management with vouchers for each weekly appointment to support treatment attendance for all subjects.

Trial Locations (2)

06519

RECRUITING

The Yale Stress Center: Yale University, New Haven

RECRUITING

The Yale Stress Center: Yale University, New Haven

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Yale University

OTHER